¼¼°èÀÇ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý ½ÃÀå
Immunoassay for Neurological Biomarkers
»óǰÄÚµå : 1781302
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 380 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý ¼¼°è ½ÃÀåÀº 2030³â±îÁö 21¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 8¾ï 990¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 17.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 21¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±â±â ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ýÀº CAGR 19.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Ã¾à ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý ºÎ¹® ºÐ¼® ±â°£ µ¿¾È CAGR ¼ºÀå·üÀº 14.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 2,060¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 23.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý ½ÃÀåÀº 2024³â¿¡ 2¾ï 2,060¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 23.2%·Î ÃßÁ¤µÇ¸ç, 2030³â±îÁö 4¾ï 7,490¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, °¢°¢ ºÐ¼® ±â°£ µ¿¾È¿¡ 12.6%¿Í 15.7%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 13.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý ½ÃÀå - ½Å°æ Áø´Ü ÇÐÀÇ Áøº¸

½Å°æÇп¡¼­ ¸é¿ªÃøÁ¤ÀÌ Áß¿äÇÑ ÀÌÀ¯

½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ýÀº ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ´Ù¹ß¼º °æÈ­Áõ µî ½Å°æÅðÇ༺ Áúȯ°ú °ü·ÃµÈ ´Ü¹éÁúÀ» °ËÃâ ¹× Á¤·®È­ÇÒ ¼ö ÀÖ¾î Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ À¯º´·ü Áõ°¡¿Í Àα¸ÀÇ °í·ÉÈ­°¡ ¸Â¹°·Á Á¶±â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸é¿ªºÐ¼®Àº Ç÷¾× ¹× ³úô¼ö¾×¿¡¼­ ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇÏ´Â ºñħ½ÀÀû ¹æ¹ýÀ» Á¦°øÇÏ¿© Àû½Ã¿¡ °³ÀÔÇϰí Áúº´À» °ü¸®ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

¸é¿ªÃøÁ¤ ±â¼úÀÇ Çõ½ÅÀº ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

°í°¨µµ ´ÙÁß ´ÙÁß¿°±â¼­¿­ºÐ¼®, µðÁöÅп°±â¼­¿­ºÐ¼® µîÀÇ ±â¼ú ¹ßÀüÀ¸·Î ½Å°æÇÐÀû Áø´ÜÀÇ Á¤È®¼º°ú È®À强ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ µ¥ÀÌÅÍ ºÐ¼®Àº ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâÀ» ´õ¿í Á¤±³È­ÇÏ¿© ½Å°æÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, POC(Point of Care)(Point of Care) ¸é¿ªÃøÁ¤ Ç÷§ÆûÀÇ °³¹ß·Î ½Å°æ Áø´ÜÀÌ ´õ¿í Ä£¼÷ÇØÁ® Àü¹® °Ë»ç ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³·¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤±âÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ È¯ÀÚ¸¦ À§ÇØ ÈÞ´ë¿ë ¹× °¡Á¤¿ë Áø´ÜŰƮµµ µîÀåÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå¿äÀÎÀº ¹«¾ùÀΰ¡?

½Å°æÅðÇ༺ ÁúȯÀÇ Á¶±â Áø´Ü¿¡ ´ëÇÑ °ü½É Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Á¦¾àȸ»ç¿Í Áø´Üȸ»çÀÇ Çù·Â °ü°è Áõ°¡´Â ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀÔ´Ï´Ù. ½Å°æÇÐ ¿¬±¸¸¦ ÃËÁøÇÏ´Â Á¤ºÎÀÇ ³ë·Â°ú ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀüµµ ½Å°æÇÐ ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâÀ» À§ÇÑ ¸é¿ªºÐ¼® ¾ÖÇø®ÄÉÀ̼ÇÀÇ ±Þ¼ÓÇÑ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à ¾÷°è´Â ÀǾàǰ °³¹ß ¹× ÀÓ»ó½ÃÇè¿¡ ¸é¿ªºÐ¼®¹ýÀ» Ȱ¿ëÇϰí ÀÖÀ¸¸ç, ±× ¿ëµµ¸¦ ´õ¿í È®ÀåÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀÇ ¹Ì·¡´Â?

À¯¸ÁÇÑ ¼ºÀå¿¡µµ ºÒ±¸Çϰí, ±ÔÁ¦Àû Àå¾Ö¹°, ºñ¿ë À庮, ¹ÙÀÌ¿À¸¶Ä¿ ÆÐ³Î Ç¥ÁØÈ­ µîÀÇ °úÁ¦¸¦ ÇØ°áÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª AI, ÀÚµ¿È­, Â÷¼¼´ë ½ÃÄö¼­ÀÇ ÅëÇÕÀÌ ÁøÇàµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ °£±ØÀ» ¸Þ¿ï ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªºÐ¼®Àº ½Å°æ Áø´Ü ¹× ȯÀÚ Ä¡·áÀÇ º¯È­¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç°(±â±â ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý, ½Ã¾à ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý, ¼­ºñ½º ½Å°æ ¹ÙÀÌ¿À¸¶Ä¿¿ë ¸é¿ªÃøÁ¤¹ý), Áúȯ(¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ´Ù¹ß¼º °æÈ­Áõ, ±âŸ Áúȯ), ¿ëµµ(ü¿ÜÁø´Ü ¿ëµµ, Á¶»ç ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Immunoassay for Neurological Biomarkers Market to Reach US$2.1 Billion by 2030

The global market for Immunoassay for Neurological Biomarkers estimated at US$809.9 Million in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 17.3% over the analysis period 2024-2030. Instruments Immunoassay for Neurological Biomarkers, one of the segments analyzed in the report, is expected to record a 19.4% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Reagents Immunoassay for Neurological Biomarkers segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$220.6 Million While China is Forecast to Grow at 23.2% CAGR

The Immunoassay for Neurological Biomarkers market in the U.S. is estimated at US$220.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$474.9 Million by the year 2030 trailing a CAGR of 23.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

Global Immunoassay for Neurological Biomarkers Market - Advancing Neurodiagnostics

Why Are Immunoassays Becoming Crucial in Neurology?

Immunoassays for neurological biomarkers are gaining significant traction due to their ability to detect and quantify proteins associated with neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The rising prevalence of these conditions, coupled with an aging population, has driven demand for early and accurate diagnostic tools. Immunoassays provide a non-invasive method for detecting neurological biomarkers in blood and cerebrospinal fluid, enabling timely intervention and disease management.

How Are Innovations in Immunoassay Technology Impacting the Market?

Technological advancements, including highly sensitive multiplex immunoassays and digital immunoassays, have improved the precision and scalability of neurological diagnostics. AI-driven data analysis is further refining biomarker detection, allowing for early-stage identification of neurological disorders. Moreover, the development of point-of-care immunoassay platforms is making neurodiagnostics more accessible, reducing dependency on specialized laboratory infrastructure. Portable and home-based diagnostic kits are also emerging, catering to patients who require regular monitoring.

What Are the Market Growth Factors?

The growing focus on early diagnosis of neurodegenerative diseases, increasing investment in biomarker research, and rising collaborations between pharmaceutical and diagnostic companies are major growth drivers in this market. Government initiatives promoting neurological research and advancements in personalized medicine are also contributing to the rapid expansion of immunoassay applications for neurological biomarker detection. Additionally, the pharmaceutical industry is leveraging immunoassays for drug development and clinical trials, further expanding their application.

What Lies Ahead for the Market?

Despite the promising growth, challenges such as regulatory hurdles, cost barriers, and standardization of biomarker panels need to be addressed. However, the increasing integration of AI, automation, and next-generation sequencing is expected to bridge these gaps. As demand for precision medicine grows, immunoassays for neurological biomarkers will play a pivotal role in transforming neurodiagnostics and patient care.

SCOPE OF STUDY:

The report analyzes the Immunoassay for Neurological Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Instruments Immunoassay for Neurological Biomarkers, Reagents Immunoassay for Neurological Biomarkers, Services Immunoassay for Neurological Biomarkers); Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis Disease, Other Diseases); Application (In Vitro Diagnostics Application, Research Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â